Posts

FDA launches pilot to accelerate Phase 1 drug trials

on

Novartis board faces investor scrutiny after M&A misfires and R&D setbacks

on

FDA signals flexibility on psychedelic drug review while keeping evidence standards

on

Tyra’s bladder-cancer data offer a bright spot—but miss investor expectations

on

Beeline’s oral lupus drug afimetoran delivers positive Phase 2 results

on

Moonwalk raises $70 million to develop fat-targeted siRNA obesity therapy

on

Novartis’s Pelacarsen Fails to Reduce Cardiovascular Risk in Phase 3 Trial

on

Roivant’s $14M Bayer Deal Shows Strong Phase 2 Results

on

Novo Nordisk halts two more IL-6 heart-drug trials for futility

on

Fierce AI Innovation Awards 2026: Winners Announced

on

BioNTech halts personalized mRNA colorectal-cancer vaccine trial

on

China’s biotech rise is becoming a U.S. national-security concern

on

Generate:Biomedicines releases early GB-0895 respiratory data after ERS poster leak

on

Spyre abandons standalone RA ambitions for SPY072 after modest Phase 2 results

on

Bausch + Lomb to pursue Phase 3 dry-eye trial despite Phase 2 endpoint miss

on

Bausch + Lomb advances Xiidra–Miebo combination to Phase 3 despite mixed Phase 2 results

on

Clinical development enters the digital age

on

Third patient death revealed in China's CAR-T and gene therapy trials, spotlighting IIT safety and transparency

on

Zenbexus: BMS earns first FDA approval for CELMoD class in multiple myeloma

on

Zealand's royalty deal

on